Mediwound Ltd
MDWD
查看详细走势图
17.790USD
+0.570+3.31%
收盘 02/06, 16:00（美东）报价延迟15分钟
228.09M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.31%
5天
-1.88%
1月
-8.16%
6月
-5.27%
今年开始到现在
-3.63%
1年
-1.88%
查看详细走势图
TradingKey Mediwound Ltd股票评分
单位: USD 更新时间: 2026-02-06操作建议
Mediwound Ltd当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名60/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价31.50。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Mediwound Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Mediwound Ltd亮点
亮点风险
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
业绩增长期
公司处于发展阶段，最新年度总收入20.22M美元
利润高增长
公司净利润处于行业前列，最新年度总收入20.22M美元
估值低估
公司最新PE估值-9.62，处于3年历史低位
机构加仓
最新机构持股6.98M股，环比增加18.62%
凯茜·伍德（木头姐）持仓
明星投资者凯茜·伍德（木头姐）持仓，最新持仓市值96.88K
活跃度增加
近期活跃度增加，过去20天平均换手率0.19
分析师目标
根据
6
位分析师
买入
评级
31.500
目标均价
+78.77%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Mediwound Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Mediwound Ltd简介
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
公司代码MDWD
公司Mediwound Ltd
CEOGonen (Ofer)
网址https://www.mediwound.com/
相关品种
